Disubstituted alkyne derivatives

A compound of formula (I)

• wherein
• W denotes CRW1 or N;
• RW1 is H, halogen, Ra or —ORa;
• R1 is —OH, —ORa, —NH2, —NHRa, —NRaRb, —N(H)OH, —N(H)O—Ra, —N(H)CN, —N(H)—C(═O)—Ra or —N(H)—SO2—Ra;
• or R1 together with R2 forms a divalent —O—CH2— or —N—CH2— radical;
• R2 is H, halogen, —CN, Ra, —OH, —ORa, NH2, —NH—Ra or —NRaRb;
• R3 is H, halogen, Ra, —OH, —ORa, NH2, —NH—Ra, —NRaRb, —NO2 or unsubstituted or substituted phenyl;
• or
• R2 and R3 form together with the carbon atoms to which they are attached to an unsubstituted or substituted six-membered aromatic ring;
• or form together a divalent —NH—CH2—CH2—NH— radical;
• R4 is H or Ra;
• R5 is H or halogen;
• R6 is H, halogen, Ra, —ORa, NH2, —NHRa, —NRaRb, —NO2 or ArA;
• R7 is H, halogen, Ra, —ORa, NH2, —NHRa, —NRaRb, —N(H)—C(═O)—Ra or —C(═O)—NHRa;
• R8 is H, halogen or Ra;
• n is an integer selected from 0 and 1;
• L1 is a divalent —NH—, —N(Ra)— or —CH2— radical;
• and
• L2 is a divalent —SO2— radical;
• and
• L3 is a divalent —CH═CH— radical;
• or
• L1 is a divalent —N(CHO)—, —N(C(═O)—Ra)—, —N(C(═O)—NH2)—, —N(C(═O)—NHRa)— or —N(C(═O)—NRaRb)— radical;
• and
• L2 is a divalent —CH2— radical;
• and
• L3 is a divalent —CH2— radical;
• or
• L1 is a divalent —CH2— radical;
• L2 is a divalent —N(CHO)—, —N(C(═O)—Ra)—, —N(C(═O)—NH2)—, —N(C(═O)—NHRa)— or —N(C(═O)—NRaRb)— radical;
• and
• L3 is a single bond;
• or
• L1 is a divalent —N=radical;
• L2 is a divalent ═S(═O)(Ra)— radical;
• and
• L3 is a single bond;
• A is a ring selected from the group consisting of ArA, HetarA, CycA and HetcycA;
• ArA is a mono-, bi- or tricyclic aryl with 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 ring carbon atoms, wherein that aryl may be unsubstituted or substituted with substituents RA1, RA2, RA3, RA4, RA5, RA6 and/or RA7 which may be the same or different, with the proviso that ArA is not 4-methylphenyl;
• HetarA is a mono-, bi- or tricyclic heteroaryl with 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 ring atoms wherein 1, 2, 3, 4, 5 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with substituents RA1, RA2, RA3, RA4RA5, RA6 and/or RA7 which may be the same or different;
• CycA is a saturated or partially unsaturated, mono-, bi- or tricyclic carbocycle with 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with RA8, RA9, RA10 and/or RA11 which may be the same or different;
• HetcycA is a saturated or partially unsaturated, mono-, bi- or tricyclic heterocycle with 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ring atoms wherein 1, 2, 3, 4, 5 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with RA8, RA9, RA10 and/or RA11 which may be the same or different;
• RA1, RA2, RA3, RA4, RA5, RA6, RA7 are independently from each other H, halogen, Ra, —ORa, —NH2, —NHRa, —NRaRb, —N(H)—C(═O)—Ra, ArB, —O—ArB, HetarB, CycB or HetcycB;
• and/or
• two adjacent RA1, RA2, RA3, RA4, RA5, RA6, RA7 may form together a divalent —C1-3-alkylene-O— or —O—C1-3-alkylene-O— radical which C1-3-alkylene may be unsubstituted or mono- or disubstituted with Ra or halogen;
• or may form together with the ring atoms to which they are attached to a CycC;
• RA8, RA9, RA10, R11 are independently from each other H or Ra;
• or a pair of RA8, RA9, RA10 and/or RA11 form a ═O radical;
• ArB is a phenyl ring, wherein that phenyl ring may be unsubstituted or substituted with substituents RB1, RB2 and/or RB3 which may be the same or different;
• HetarB is a monocyclic heteroaryl with 5, 6, 7 ring atoms wherein 1, 2, 3, 4 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroryl may be unsubstituted or substituted with substituents RB1, RB2 and/or RB3 which may be the same or different;
• CycB is a mono- or bicyclic saturated or partially unsaturated carbocycle with 5, 6, 7, 8, 9, 10 ring carbon atoms wherein that carbocycle may be unsubstituted or mono-, di- or trisubstituted with RB4, RB5 and/or RB6 which may be the same or different;
• HetcycB is a saturated or partially unsaturated monocyclic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1, 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or mono-, di- or trisubstituted with RB4, RB5 and/or RB6 which may be the same or different;
• CycC is a mono- or bicyclic saturated or partially unsaturated carbocycle with 5, 6, 7, 8, 9, 10 ring carbon atoms wherein that carbocycle is fused to ArA or HetarA via 2 adjacent ring atoms of said ArA or HetarA and wherein that carbocycle may be unsubstituted or substituted with RC1, RC2, RC3, RC4, RC5, RC6 which may be the same or different;
• RB1, RB2 and/or RB3 are independently from each other H, halogen, Ra, —ORa or —SRa;
• RB4, RB5, RB6, RC1, RC2, RC3, RC4, RC5, RC6 are independently from each other H or Ra;
• Ra, Rb are independently from each other unsubstituted or substituted, straight-chain or branched C1-6-aliphatic or may form together with the nitrogen atom to which they are attached to an unsubstituted or substituted saturated, partially unsaturated or aromatic heterocycle with 4, 5, 6, 7 ring atoms wherein 1, 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms;
• or derivatives, N-oxides, prodrugs, solvates, tautomers or stereoisomers thereof and/or the pharmaceutically acceptable salts of each of the foregoing;
• with the proviso that
• (a) 4-{2-[5-chloro-2-(4-chlorobenzenesulfonamido)phenyl]ethynyl}-benzoic acid;
• (b) methyl 4-{2-[5-chloro-2-(4-chlorobenzenesulfonamido)phenyl]-ethynyl}benzoate;
• and
• (c) methyl 4-{2-[2-(N-benzyl-2,2,2-trifluoroacetamido)phenyl]ethynyl}-benzoate
• are excluded.